Pursuits
Biotech Stocks Are on the Brink of a Correction
This article is for subscribers only.
The bull run in biotechnology is having its worst month in more than a year.
Down in four of the last five days, companies tracked by the Nasdaq Biotechnology Index have fallen about 8 percent since July 20. They’re in danger of joining more than half the stocks in the Standard & Poor’s 500 Index nursing losses that meet the definition of a correction.